GDF15 levels increase significantly in patients with obesity and normoglycemia and in those with obesity and impaired glucose tolerance or type 2 diabetes, while FGF21 concentrations significantly decrease in patients with obesity and impaired glucose tolerance or type 2 diabetes. Here, GDF15 is linked to obesity due to melanocortin 4 receptor deficiency.